What is Anacor Pharmaceuticals Financial Strength?
Anacor Pharmaceuticals has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Anacor Pharmaceuticals did not have earnings to cover the interest expense.
Anacor Pharmaceuticals's debt to revenue ratio for the quarter that ended in Mar. 2016 was 0.89.
As of today, Anacor Pharmaceuticals's Altman Z-Score is 0.00.
Competitive Comparison of Anacor Pharmaceuticals's Financial Strength
For the Biotechnology subindustry, Anacor Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anacor Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anacor Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Anacor Pharmaceuticals's Financial Strength falls into.
Anacor Pharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Anacor Pharmaceuticals's Interest Expense for the
months ended in Mar. 2016 was $-1.43 Mil. Its Operating Income for the
months ended in Mar. 2016 was $-14.92 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2016 was $62.26 Mil.
Anacor Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2016 is
| Anacor Pharmaceuticals did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Anacor Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Mar. 2016 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Anacor Pharmaceuticals has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anacor Pharmaceuticals (Anacor Pharmaceuticals) Business Description
Traded in Other Exchanges
N/A
Address
Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company's main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of people. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.
Executives
| Keith R Leonard |
director |
ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
| William Jl Rieflin |
director |
NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080 |
| Anders D Hove |
director |
30 ROCKEFELLER PLAZA, SUITE 5508, NEW YORK NY 10112 |
| Lucy Shapiro |
director |
10210 GENETIC CENTER COURT, SAN DIEGO CA 92121 |
| Graeme Bell |
officer: Executive VP and CFO |
1324 WAVERLY ROAD, GLADWYNE PA 19035 |
| Ryan T Sullivan |
officer: EVP and General Counsel |
C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07855 |
| Wendall Wierenga |
director |
12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130 |
| Paul L Berns |
director, officer: President and CEO |
11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020 |
| Mark Leschly |
director |
RHO CAPITAL PARTNERS, INC., 152 W 57TH ST 23RD FL, NEW YORK NY 10019 |
| Geoffrey M. Parker |
officer: Executive Vice President & CFO |
15 RIORDAN PLACE, MENLO PARK CA 94025 |
| Paul H Klingenstein |
director |
428 UNIVERSITY AVE, C/O ACCEL PARTNERS, PALO ALTO CA 94301 |
| David P Perry |
director, officer: President and CEO |
1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303 |
| Rho Management Ventures Iv Llc |
10 percent owner |
124 DUNE RD, QUOGUE NY 11959 |
| Rho Ventures Iv Qp Lp |
10 percent owner |
124 DUNE RD, QUOGUE NY 11959 |
| Rho Ventures Iv Lp |
10 percent owner |
124 DUNE ROAD, QUOGUE NY 11959 |
Anacor Pharmaceuticals (Anacor Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANAC has been successfully added to your